Senti Bio Advances SENTI-202 Toward Registration with Positive FDA RMAT Meeting and Donor Phenotype Breakthrough
Event summary
- Senti Bio plans a single-arm, multi-center pivotal trial for SENTI-202 in relapsed/refractory AML following a positive FDA RMAT meeting.
- Phase 1 data shows 50% composite CR rate in patients receiving SENTI-202 from Donor X-derived NK cells.
- All future SENTI-202 manufacturing will use Donor X material, identified as a key efficacy correlate.
- SENTI-202 demonstrates durable MRD-negative responses, with some patients in remission for over 21 months.
The big picture
Senti Bio's strategic shift toward Donor X-derived NK cells for SENTI-202 manufacturing marks a critical inflection point in its quest for a registrational study. The positive FDA RMAT meeting accelerates its path toward potential approval, while the durable efficacy data positions SENTI-202 as a competitive contender in the relapsed/refractory AML space. The company's ability to leverage its Gene Circuit platform to refine donor selection underscores its commitment to precision in cell therapy development.
What we're watching
- Clinical Validation
- Whether the Donor X phenotype optimization will translate into sustained efficacy in the pivotal trial.
- Regulatory Pathway
- The pace at which Senti Bio can advance SENTI-202 through the expedited RMAT pathway.
- Market Positioning
- How Senti Bio positions SENTI-202 against existing and emerging therapies for relapsed/refractory AML.
Related topics